Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07087613 · ClinicalTrials.gov registry record

Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG

A clinical trial of Heart Failure With Reduced Ejection Fraction and Hypertension, Pulmonary, sponsored by Eko Devices.

Recruiting
Registry status
3,850
Enrollment target
3
Study locations

NCT07087613: Recruiting study of Heart Failure With Reduced Ejection Fraction and Hypertension, Pulmonary, sponsored by Eko Devices.

NCT07087613 is a study of Heart Failure With Reduced Ejection Fraction and Hypertension, Pulmonary that is actively recruiting participants, run by Eko Devices. The registered enrollment target is 3,850 participants, roughly in line with the 3,823-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target. The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07087613, a study of Heart Failure With Reduced Ejection Fraction and Hypertension, Pulmonary, is actively recruiting participants, sponsored by Eko Devices.

RECRUITING
Registry status
3,850 participants
Enrollment target
3
Study locations

Study Summary

This is a prospective, observational study evaluating whether heart sounds (phonocardiograms) and three-lead electrocardiograms (ECGs) recorded using the Eko CORE 500 digital stethoscope can help detect pulmonary hypertension (PH) and low left ventricular ejection fraction (EF ≤ 40%). PH is a condition characterized by high blood pressure in the pulmonary arteries, which can lead to heart failure and carries significant risks if undiagnosed. Low EF, which indicates reduced pumping ability of the heart, is also associated with increased risk of severe cardiac events but can remain undetected because patients often have no symptoms or only nonspecific symptoms. In this study, adults undergoing clinically indicated echocardiograms at outpatient sites will be invited to participate. Participants will complete a single study session lasting about 20 minutes, during which heart sounds and a three-lead ECG will be collected using the Eko CORE 500 device. If participants have had a clinical 12-lead ECG within 30 days of their echocardiogram, those data may also be used for analysis. The echocardiogram performed as part of routine care within seven days before or after the Eko CORE 500 recording will serve as the reference standard to confirm the presence or absence of PH and low EF. Up to 3,850 participants may be enrolled across multiple sites to ensure that approximately 3,500 complete the study. The data collected will be used to develop and validate artificial intelligence (AI) algorithms that aim to detect PH and identify low EF, potentially enabling earlier and simpler screening for these conditions in clinical practice.

Primary Outcome

The primary outcome is the diagnostic performance of the algorithm developed from Eko CORE 500 recordings to detect pulmonary hypertension, as confirmed by clinical echocardiography or right heart catheterization. Sensitivity and specificity will be calculated by comparing algorithm predictions to the echocardiogram or right heart catheterization gold standard.

Interventions

  • DEVICE Eko CORE 500 Digital Stethoscope

Study Locations (3)

Illinois

  • Prairie Cardiovascular - O'Fallon
  • Prairie Education & Research Cooperative - Springfield
  • St Johns Hospital, Springfield - Springfield

Trial Details

FieldValue
Enrollment Target 3,850 participants
Start Date 2025-06-15
Est. Completion 2026-08-31
Eko Devices

16 total trials

What NCT07087613 shows while recruiting

NCT07087613 is an observational study that tracks outcomes without assigning an intervention. Its 3,850 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 3,823-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target.

The record links to 2 conditions, with Heart Failure With Reduced Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which Eko CORE 500 Digital Stethoscope is the first listed.

NCT07087613 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT07087613 about?

NCT07087613 is a clinical study titled "Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG". This is a prospective, observational study evaluating whether heart sounds (phonocardiograms) and three-lead electrocardiograms (ECGs) recorded using the Eko CORE 500 digital stethoscope can help detect pulmonary hypertension (PH) and low left ventricular ejection fraction (EF ≤ 40%). PH is a condit...

What is the current status of trial NCT07087613?

This trial is currently recruiting. The enrollment target is 3,850 participants. The study started on 2025-06-15. Estimated completion is 2026-08-31.

What conditions does trial NCT07087613 study?

This clinical trial studies the following conditions: Heart Failure With Reduced Ejection Fraction, Hypertension, Pulmonary.

What interventions are being tested in trial NCT07087613?

The interventions under investigation include: Eko CORE 500 Digital Stethoscope (DEVICE).

Who is sponsoring clinical trial NCT07087613?

This trial is sponsored by Eko Devices, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07087613 being conducted?

This trial has 3 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure With Reduced Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07087613's enrollment target sits among peer trials

3,850 4th of 27 higher than 24 of 27 other Heart Failure With Reduced Ejection Fraction trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure With Reduced Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05919342 · 3,904 participants · NA

    Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"

  • NCT04573660 · 3,784 participants

    Abbott Vascular Medical Device Registry

  • NCT03936335 · 3,930 participants

    An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

  • NCT06172660 · 3,750 participants

    Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07087613, the US trial registry maintained by the National Library of Medicine. NCT07087613 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.